Mixed agonist-antagonist properties of clozapine at different human cloned muscarinic receptor subtypes expressed in Chinese hamster ovary cells

Neuropsychopharmacology

Volumn 20, Issue 3, 1999, Pages 263-270

  Olianas, Maria C ^a   Maullu, Carlo ^a   Onali, Pierluigi ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

35S GTP S Binding; Atropine; Chinese hamster ovary cells; Clozapine; Human muscarinic receptor subtypes; Receptor binding; Second messengers

Indexed keywords

ADENYLATE CYCLASE; CARBACHOL; CLOZAPINE; CYCLIC AMP; INOSITOL PHOSPHATE; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; MUSCARINIC RECEPTOR; RECEPTOR SUBTYPE;

ANIMAL CELL; ANTICHOLINERGIC EFFECT; ARTICLE; CHO CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG RECEPTOR BINDING; HAMSTER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR AFFINITY;

ANIMALS; ANTIPSYCHOTIC AGENTS; ATROPINE; BINDING SITES; CELL MEMBRANE; CHO CELLS; CLONING, MOLECULAR; CLOZAPINE; CRICETINAE; CYCLIC AMP; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HUMANS; INOSITOL PHOSPHATES; MUSCARINIC AGONISTS; MUSCARINIC ANTAGONISTS; N-METHYLSCOPOLAMINE; RECEPTOR, MUSCARINIC M1; RECEPTOR, MUSCARINIC M2; RECEPTOR, MUSCARINIC M3; RECEPTORS, MUSCARINIC; SULFUR RADIOISOTOPES;

EID: 0032949974     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(98)00048-7     Document Type: Article

References (36)

1. Ashby C.R. Jr., Wang R.Y. Pharmacological actions of the atypical antipsychotic drug clozapine. A review Synapse. 24:1996;349-394.
2. Baldessarini R.J., Frankenburg F.R. Clozapine. A novel antipsychotic agent New Engl J Med. 324:1991;746-754.
3. Barnes T.R.E., McPhillips M.A. Antipsychotic-induced extrapyramidal symptoms. Role of anticholinergic drugs in treatment. CNS Drugs. 6:1996;315-330.
4. Berridge M.J., Dawson R.M.C., Downes C.P., Heslop J.P., Irvine R.F. Changes in the levels of inositol phosphates after agonist-dependent hydrolysis of membrane phosphoinositides. Biochem J. 212:1983;473-482.
5. Bolden C., Cusack B., Richelson E. Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells. J Pharmacol Exp Ther. 260:1992;576-580.
6. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 72:1976;248-254.
7. Casey D.E. Clozapine. Neuroleptic-induced EPS and tardive dyskinesia Psychopharmacology. 99:1989;S47-S53.
8. Cawley T.A., Shickley T.J., Ruggeri M.R., Luthin G.R. Effect of chronic neuroleptic treatment on central and peripheral muscarinic receptors. J Pharmacol Exp Ther. 267:1993;134-139.
9. Fjalland B., Christensen A.V., Hyttel J. Peripheral and central muscarinic receptor affinity of psychotropic drugs. Naunyn-Schmiedeberg's Arch Pharmacol. 301:1977;5-9.
10. Fritze J., Ellinger T. Pirenzepine for clozapine-induced hypersalivation. Lancet. 346:1995;1034.
11. Gerlach J., Lublin H., Peacock L. Extrapyramidal symptoms during long-term treatment with antipsychotics. Neuropsychopharmacology. 14:1996;35S-39S.
12. Herrling P.L., Misbach-Lesenne B. Effects of clozapine in a selective muscarinic bioassay and on single cells of the rat hippocampus. Naunyn-Schmiedeberg's Arch Pharmacol. 320:1982;20-25.
13. 4 subtypes of muscarinic receptors in transfected CHO cells and of muscarinic receptors in the heart cells revealed by negative antagonists. FEBS Lett. 377:1995;275-279.
14. Kenakin T.P. Pharmacologic Analysis of Drug-Receptor Interaction. 1987;Raven Press, New York.
15. Lazareno S., Farries T., Birdsall N.J.M. Pharmacological characterization of guanine nucleotide exchange reactions in membranes from CHO cells stably transfected with human muscarinic receptors M1-M4. Life Sci. 52:1993;449-456.
16. Lieberman J.A., Kane J.M., Johns C.A. Clozapine. Guidelines for clinical management J Clin Psychiatr. 50:1989;329-338.
17. Lieberman J.A., Saltz B.L., Johns C.A., Pollack S., Borenstein M., Kane J. The effects of clozapine on tardive dyskinesia. Br J Psychiatr. 158:1991;503-510.
18. Meltzer H.Y. Atypical antipsychotic drugs. Bloom E.F., Kupfer D.J. Psychopharmacology. The Fourth Generation of Progress:1995;1277-1286 Raven Press, New York.
19. Meltzer H.Y., Chai B.L., Thompson P.A., Yamamoto B.K. Effect of scopolamine on the efflux of dopamine and its metabolites after clozapine, haloperidol or thioridazine. J Pharmacol Exp Ther. 268:1994;1452-1461.
20. Miller R.J., Hiley C.R. Antimuscarinic properties of neuroleptics and drug-induced parkinsonism. Nature. 268:1974;596-597.
21. Miller R.J., Hiley C.R. Anti-dopaminergic and anti-muscarinic effects of dibenzodiazepines. Relationship to drug-induced parkinsonism Naunyn-Schmiedelberg's Arch Pharmacol. 292:1976;289-293.
22. Munson P.J., Rodbard D. LIGAND. A versatile computerized approach for the characterization of ligand-binding systems Anal Biochem. 107:1980;220-239.
23. Niemegeers C.J.E., Awouters F., Lenaerts F.M., Vermeire J., Janssen P.A.J. Prevention of physostigmine-induced lethality in rats. A pharmacological analysis. Arch Int Pharmacodyn. 259:1982;153-165.
24. Olianas M.C., Maullu C., Onali P. Effects of clozapine on rat striatal muscarinic receptors coupled to inhibition of adenylyl cyclase activity and on the human cloned m4 receptor. Br J Pharmacol. 122:1997;401-408.
25. Peralta E.G., Ashkenazi A., Winslow J.W., Smith D.H., Ramachandran J., Capon D.J. Differential regulation of Pi hydrolysis and adenylyl cyclase by muscarinic receptor subtypes. Nature. 334:1988;434-437.
26. Pfeiffer C.C., Jenney E.H. Inhibition of the conditioned response and the counteraction of schizophrenia by muscarinic stimulation of the brain. Ann NY Acad Sci. 66:1957;753-764.
27. Racagni G., Cheney D.L., Trabucchi M., Costa E. In vivo actions of clozapine and haloperidol on the turnover rate of acetylcholine in rat striatum. J Pharmacol Exp Ther. 196:1976;323-332.
28. Rivest R., Marsden C.A. Muscarinic antagonists attenuate the increase in accumbens and striatum dopamine metabolism produced by clozapine but not by haloperidol. Br J Pharmacol. 104:1991;234-238.
29. Rosenthal R., Bigelow L.B. The effects of physostigmine in phenothiazine resistant chronic schizophrenic patients. Preliminary observations Comp Psychiatr. 14:1973;489-494.
30. Salomon Y., Londos D., Rodbell M. A highly sensitive adenylate cyclase assay. Anal Biochem. 58:1974;541-548.
31. 3H]quinuclidinyl benzilate binding assay with conventional methods J Pharm Pharmacol. 28:1976;252-253.
32. Snyder S.H., Greenberg D., Yamamura H.I. Antischizophrenic drugs and brain cholinergic receptors. Arch Gen Psychiatr. 31:1974;58-61.
33. Tandon R., DeQuardo J.R., Goodson J.-A., Mann N.A., Greden J.F. Effect of anticholinergics on positive and negative symptoms in schizophrenia. Psycopharmacol Bull. 28:1992;297-302.
34. Vogel W.K., Mosser V.A., Bulseco D.A., Schimerlik M.I. Porcine m2 muscarinic acetylcholine receptor-effector coupling in Chinese hamster ovary cells. J Biol Chem. 270:1995;15485-15493.
35. Zeng X.P., Le F., Richelson E. Muscarinic m4 receptor activation by some atypical antipsychotic drugs. Eur J Pharmacol. 321:1997;349-354.
36. 4 receptor agonist. Eur J Pharmacol-Mol Pharmacol Sect. 269:1994;R1-R2.